Helmizol

Quick links to important sections

Helmizol

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Helmizol

Helmizol is an anthelmintic medication, a type of drug specifically designed to treat infections caused by parasitic worms in the body.

Property Description
Active ingredient Albendazole
Form Tablet (Oral)
Pharmacological class Benzimidazole Anthelmintic
Common use Clears parasitic worm infestations
Origin Synthetic small molecule

The Core Identity and Composition

Helmizol is a prescription medicine (Rx) whose core therapeutic activity is derived from the active ingredient Albendazole. This substance chemically classifies the medicine within the benzimidazole carbamate pharmacological class. Albendazole is a synthetic compound manufactured to deliver systemic antiparasitic action throughout the body. The medication is typically manufactured as a single-ingredient product, prepared as an oral tablet using essential pharmaceutical excipients for stability and structure.

Albendazole acts as a broad-spectrum agent against intestinal and systemic parasitic infections. The medication is designed to target and manage the presence of internal parasites, a function recognized by international health bodies.

General Therapeutic Purpose

The overall therapeutic purpose of Helmizol is to clear the body of parasitic worm infestations. The drug is used in general practice to address conditions where helminths (parasitic worms) are identified as the root cause. Albendazole is categorized as a benzimidazole anthelmintic. The medication's targeted action on the parasite's cell structure prevents the worms from properly absorbing nutrients, leading to their depletion of energy and eventual eradication, thereby resolving the underlying infection.

Regulatory References

  1. Albendazole (StatPearls - NCBI)

What side effects are possible with Helmizol?

Possible Side Effects and Safety Information

The safety profile of Helmizol (Albendazole) is defined by official regulatory documents, which categorize potential adverse reactions by the organ system affected and their reported frequency. The most common effects are generally non-serious and transient.


Organ System Safety Patterns and Frequencies

Adverse reactions involving the Hepatobiliary Disorders (liver) are of primary concern. Elevated hepatic enzymes (transaminases) are classified as a very common finding. These changes are typically reversible upon stopping treatment. Common effects include Nervous System Disorders such as headache and dizziness, as well as Gastrointestinal Disorders like abdominal pain, nausea, and vomiting.

Reversible alopecia (hair thinning) is also a common effect, usually resolving after the medicine is discontinued. The experience of fever is another commonly reported systemic effect.


Serious Adverse Reactions and Safety Constraints

Regulatory labels document the potential for rare but serious adverse reactions, particularly involving the Blood and Lymphatic System Disorders. These include bone marrow suppression leading to leukopenia or pancytopenia (severe reduction in blood cells), which necessitates periodic monitoring of blood counts during therapy. Severe cutaneous reactions, such as Stevens-Johnson Syndrome (SJS), have also been reported.

Safety constraints noted in prescribing information include the medicine being contraindicated in pregnancy; individuals of childbearing potential must use effective contraception during and for a period after treatment. The risk of significant effects, particularly on the blood and liver, is associated with the long-term therapy required for systemic parasitic infections.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Helmizol (fingolimod) primarily affects the cardiovascular system, potentially causing serious and prolonged heart problems. The most critical documented presentations involve severe bradycardia (abnormally slow heart rate) and atrioventricular (AV) conduction block, which is a delay or blockage of electrical signals in the heart.

Symptoms and Emergency Action

Immediate medical attention is necessary if an overdose is suspected or if you experience symptoms like dizziness, unusual tiredness, or the sensation that your heart is beating slowly or skipping beats. Individuals should immediately call for emergency medical help or go to the nearest emergency room.

Due to the way fingolimod is absorbed and eliminated by the body, the most severe effects may have a delayed onset, appearing many hours after ingestion. For this reason, official regulatory information mandates that patients who have taken an overdose must be placed under extended medical monitoring, often overnight, to ensure that the cardiac abnormalities resolve. If necessary, specific treatments, such as atropine or isoprenaline, may be administered by medical staff to reverse the cardiac effects.

Therapeutic Uses of Helmizol

What Helmizol Treats: Main Uses and Benefits

Helmizol (Albendazole) is commonly used across two major therapeutic domains related to parasitic infection: systemic cestode diseases and intestinal helminthiasis. This broad applicability allows the medicine to be applied in contexts involving heightened systemic burden or localized discomfort.


Addressing Severe Systemic Parasitic Conditions

This medication is commonly used to treat severe infections caused by tapeworm larvae, which form parasitic cysts in vital body areas. These conditions include Neurocysticercosis, a condition where symptoms are related to neurological manifestations, and Cystic Hydatid Disease, which involves cysts in organs like the liver or lungs. Helmizol is applied in settings marked by temporary physiological imbalance to address pronounced symptoms such as seizures and chronic severe headaches. The primary therapeutic purpose is to assist with maintaining functional stability and support general well-being during symptomatic phases related to disease progression.

“The primary therapeutic purpose is to assist with maintaining functional stability and support general well-being during symptomatic phases.”

Managing Common Intestinal Worm Infestations

Helmizol is also a primary treatment for managing the presence of parasitic worms that reside in the intestines. This includes managing conditions like roundworm (Ascariasis), pinworm (Enterobiasis), hookworm infections, and whipworm (Trichuriasis). This drug is used across conditions where symptoms may intensify temporarily, such as those that cluster into patterns of symptomatic discomfort like abdominal pain, general malaise, and systemic fatigue. This therapeutic action is used for managing the parasitic organisms, which contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Abdominal Discomfort

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Helmizol? (Official Regulatory Information)

Helmizol (Albendazole) eligibility is strictly defined by regulatory authorities based on three core domains: Hypersensitivity, Reproductive Status, and Organ Function.


Populations That Must Not Use Helmizol (Contraindications)

Category Restriction Status
Hypersensitivity Known allergy to Albendazole or the benzimidazole class of compounds. Contraindicated
Pregnancy Women who are pregnant or suspected to be pregnant. Contraindicated

Populations Requiring Conditional Use

  • Females of Reproductive Potential: Must have a negative pregnancy test before initiating therapy and use effective contraception during treatment and for at least one month afterward.
  • Pediatric Use: Generally not recommended for children under two years of age for common infections due to limited clinical experience.
  • Hepatic Impairment: Use requires caution in patients with pre-existing liver disease or abnormal liver enzyme test results, with enzyme levels requiring monitoring every two weeks.
  • Bone Marrow Status: Caution is required for patients with pre-existing bone marrow suppression (e.g., pancytopenia); blood counts must be monitored frequently.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Helmizol

Interaction Scope

Category Official Regulatory Information
Medicinal product categories with documented interactions Anticonvulsants, Anti-helminthics, Glucocorticoids, H2 Receptor Antagonists, Antivirals, Immunosuppressants.
Specific interacting medicines (if explicitly listed) Phenytoin, Rifampicine, Cimetidine, Fluconazole, Dexamethasone, Praziquantel, Acalabrutinib, Ropeginterferon alfa 2b.
Mechanistic basis of interactions (only if stated in label) Metabolic Induction (decrease exposure of active metabolite); Metabolic Inhibition (increase exposure of active metabolite); Pharmacodynamic Synergism (additive myelosuppressive effects).
Timing-based interaction rules (if applicable) Mandatory co-administration with a fatty meal is required to significantly increase the bioavailability and systemic exposure of the active metabolite, Albendazole sulfoxide.
Population-specific interaction notes (if applicable) Patients with pre-existing liver disease or hepatic echinococcosis are noted to have an increased risk for severe adverse co-toxicity, such as bone marrow suppression.
Interaction-related restrictions Substance Restriction: Ingestion with Grapefruit Juice is documented to significantly increase plasma concentrations of the active metabolite.

Interaction Classifications (High-Level)

Category Official Regulatory Information
Interaction severity classification (as defined in official documents) Clinically Significant (due to major pharmacokinetic alterations); Use with Caution (due to additive toxicity risk).
Regulatory basis (EMA / FDA / etc.) Information derived from FDA prescribing information and EMA Summary of Product Characteristics (SmPC) equivalents.
Interaction-context constraints (as defined in official documents) Administration Constraint: Mandatory co-administration with a fatty meal to achieve necessary therapeutic exposure.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration with enzyme inducers like Phenytoin or Rifampicine results in decreased plasma concentrations of the active metabolite, Albendazole sulfoxide.
  • Praziquantel and Dexamethasone co-administration is documented to increase the Cmax and AUC of Albendazole sulfoxide by approximately 50% and 56%, respectively.
  • There is a documented risk of additive myelosuppression when Helmizol is co-administered with other myelosuppressive agents, such as Acalabrutinib.

Connection to the overall interaction profile (2–4 sentences): Regulatory documents define the product's interaction structure primarily through pharmacokinetic changes, detailing specific medicines that significantly modify the exposure of the active metabolite via metabolic induction or inhibition. The profile includes essential administration constraints related to food for required bioavailability and notes pharmacodynamic interactions that increase the risk of additive toxicity. This framework identifies the substances and conditions that lead to documented alterations in the product's systemic disposition or co-toxicity risk.

Mechanism of Action

Selective Microtubule Inhibition

The drug's active form, albendazole sulfoxide, selectively targets and binds to the beta-tubulin protein subunit predominantly found in the parasitic worm's cells. This binding specifically and irreversibly inhibits the polymerization of beta-tubulin, causing the disintegration and subsequent loss of functional cytoplasmic microtubules within the parasite's cellular structure.


Energy Metabolism Collapse and Starvation

Microtubule disruption severely impairs the worm's intestinal and tegumental cells, critically blocking the helminthic glucose utilization pathway. By preventing the uptake and transport of glucose, the drug initiates a cascade that rapidly depletes the parasite’s stored glycogen reserves and halts ATP production. This energy metabolism failure is the definitive physiological consequence, leading to the worm’s rapid immobilization and the cessation of vital metabolic processes.


Mechanism Dependence and Selectivity Threshold

The drug requires bioactivation in the host liver, where the administered compound is converted into the active albendazole sulfoxide metabolite, which then mediates the systemic anthelmintic effect. Although the drug demonstrates high selectivity for parasitic beta-tubulin, its mechanism is concentration-dependent; high systemic levels can still cause a temporary inhibitory effect on rapidly dividing human host cells (e.g., bone marrow), defining the boundaries of its selective toxicity.

Dosage and Administration Information

Helmizol (Albendazole) is an oral medication with two distinct administration patterns depending on the infection's location and severity. This structured approach, categorized by weight, frequency, and duration, is utilized in the administration of the drug.


Route and Administration Conditions

The medication is administered exclusively via the oral route as a tablet or suspension. To maximize its systemic absorption, particularly for severe infections, Helmizol is typically taken with food, preferably a fatty meal. The tablets may be crushed or chewed and swallowed with water for patients who have difficulty with whole pills.

Dosing and Duration Regimens

Dosing regimens vary between single-dose, fixed-term, and cyclic use.

  • Intestinal Helminthiasis: For common infections, administration is often a single 400 mg dose. For pinworm, the protocol generally calls for the single dose to be repeated after two weeks.
  • Systemic Cestode Infections: For conditions like Neurocysticercosis, the standard adult regimen is 400 mg twice daily (BID). Dosage is adjusted for lighter patients, requiring a weight-based dose of 15 mg/kg/day divided BID, not to exceed 800 mg total daily.
  • Cyclic Use: Treatment for Cystic Hydatid Disease follows a precise regimen: a 28-day course followed by a 14-day drug-free interval, repeated up to three times.

In the event of a missed dose, the standard procedure is to take it as soon as possible unless the next dose is due, preventing the use of a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Helmizol

The research on Helmizol (Albendazole) was evaluated in studies against different parasitic worm infections, with evidence ranging from controlled trials to observational reports. This section describes the structure of the available evidence, what researchers have examined so far, and where limitations or uncertainty may exist.


Evidence for Use in Severe Systemic Parasitic Conditions

Research exploring how symptoms change over time often involves studies examining temporary physiological imbalance. These conditions are characterized by functional limitations.

The Study Landscape for Neurocysticercosis

Helmizol was studied for Neurocysticercosis (NCC), a condition where tapeworm cysts form in the brain. Research includes Randomized Controlled Trials (RCTs) and systematic reviews. These studies monitored both radiological outcomes (cyst resolution on scans) and clinical outcomes (tracking seizure frequency). Findings describe patterns observed regarding cyst status, but results were mixed when tracking specific changes in neurological outcomes. Research limitations include inconsistent findings across trials concerning symptom outcomes and limited information for long-term outcomes.

Research for Cystic Hydatid Disease

Helmizol was evaluated in research concerning Cystic Hydatid Disease (CHD), where cysts form in organs. The evidence base includes a combination of Randomized Controlled Trials and long-term clinical experience reports. Studies examined primarily radiological outcomes, tracking measurements of cyst size and degeneration. The evidence quality varies across studies, and comparative evidence is lacking for certain scenarios.


Evidence for Common Intestinal Worm Infestations

Research has extensively examined the use of Helmizol against common intestinal worm infestations (soil-transmitted helminths). The key measurements used in this research examined microbiological outcomes, specifically the Cure Rate (CR) and the Egg Reduction Rate (ERR). Studies report patterns of parasite clearance in many individuals. However, the data show patterns related to variable efficacy across different parasitic worms was observed in some studies. Clearance rates were consistently lower for certain parasites, such as whipworm (Trichuris trichiura).


What the Research Indicates is Still Unknown

Research highlights what is known—and what is still uncertain—about Helmizol's use. The long-term effects are not fully established across all indications, and the follow-up durations were limited for many trials. These limitations mean research is ongoing to address these uncertainties.

Key Studies & References

  1. Evidence-based guideline: Treatment of parenchymal neurocysticercosis - American Epilepsy Society
  2. Albendazole for the Treatment of Human Echinococcosis: A Review of Comparative Clinical Trials
  3. Efficacy of Single-Dose Albendazole for the Treatment of Soil-Transmitted Helminthic Infections among School Children in Rwanda—A Prospective Cohort Study
  4. Albendazole: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Helmizol (FAQ)

Q: Are there any common over-the-counter pain relievers that interact with Helmizol?

According to regulatory-derived information, major pharmacokinetic interactions with common non-prescription pain relievers such as acetaminophen or ibuprofen have not been frequently documented. However, official guidance recommends that patients inform their healthcare provider about every medicine they use, including non-prescription products.


Q: How long do common side effects from Helmizol generally last after starting treatment?

Official product information describes common side effects, like headache or stomach upset, as transient, meaning they are temporary. Official information notes that these effects are generally transient and may lessen or resolve as the treatment course progresses or once the medication is stopped.


Q: Why do some patients report feeling no immediate difference when they first start taking Helmizol?

The official mechanism of action explains that Helmizol works by a process of parasitic starvation, slowly causing the depletion of the worm’s energy reserves. Because the medication's action is gradual, the full therapeutic effect and noticeable clinical improvement may not be immediate and can take time to develop.


Q: Is it possible to take Helmizol while using birth control medication?

Regulatory guidance establishes that women of childbearing potential must use appropriate contraception during and after Helmizol therapy. Official documents note a theoretical risk of interaction when Helmizol is co-administered with oral contraceptives.


Q: What is the significance of the specific dosing frequency (e.g., once or twice a day) for Helmizol?

The official product information explains that the dosing frequency is guided by the medication's pharmacokinetic profile. This profile is designed to support the maintenance of the active substance within the therapeutic range required to fight the parasitic infection.


Q: How should patients react if they experience an allergic reaction to Helmizol?

If signs of a severe allergic reaction occur—including difficulty breathing, swelling of the face, or a severe rash—official guidance directs that patients immediately seek emergency medical assistance. This guidance is based on the safety instructions provided in the patient information leaflet.


Q: Are there any specific activities or sports that are discouraged while taking Helmizol?

Patients who develop a serious side effect called myelosuppression (low blood cell counts) may be susceptible to injury. For these patients, the warnings and precautions section notes that avoidance of contact sports or activities with risk of injury is relevant.


Q: Is it described in the patient information leaflet that alcohol should be avoided with Helmizol?

Official product information contains a warning that the consumption of alcohol is noted to increase the risk of liver problems (hepatotoxicity) when used alongside Helmizol. For this reason, alcohol should be limited or avoided during treatment.


Q: Is fatigue or tiredness listed among the most frequently reported side effects?

While not always listed as a common primary side effect, official post-marketing reports have documented asthenia (tiredness and weakness). Furthermore, excessive fatigue can be a sign related to anemia, which is a possible blood-related side effect of the medication.


Q: Is there any evidence to suggest that Helmizol can affect the ability to drive or use machinery?

Safety warnings indicate that the ability to drive or use machinery may be affected by side effects such as dizziness. Official guidance states that patients must wait to operate vehicles or machinery until the effect of Helmizol on their alertness is known.


Q: Does official information indicate that Helmizol affects sleep patterns?

Official post-marketing experience reports have documented somnolence (drowsiness or excessive sleepiness) as a possible adverse reaction. This is classified as a nervous system disorder noted in the safety section of the product labeling.


Q: What is the typical time frame for a follow-up consultation after starting Helmizol?

For patients undergoing continuous therapy, official safety guidelines describe the necessity of frequent monitoring, including blood cell and liver enzyme checks. This monitoring is typically scheduled at the beginning of each treatment cycle and at least every two weeks while the patient is on the medication.


Q: What should a patient do if they accidentally take more Helmizol than prescribed?

If a patient suspects they have taken more than the prescribed amount of Helmizol (overdose), official guidance directs that emergency medical assistance should be sought immediately. Symptoms of overdose may include lethargy and loss of appetite.


Q: Is it true that Helmizol can cause changes in appetite?

Loss of appetite has been reported in the safety information, often linked to symptoms of a potential liver problem. It is also noted as a possible symptom in the event of an overdose.

How should Helmizol be stored and disposed of?

How to Store and Dispose of Helmizol (Albendazole)

Helmizol must be stored according to regulatory requirements to preserve product stability. The tablets should be kept at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and must be kept from freezing.

Storage Conditions

The medication must be stored in its original, tightly closed container and kept away from excess heat and moisture (such as the bathroom). It must be placed out of the sight and reach of children.

Disposal Instructions

Unused or expired Helmizol must not be flushed down the toilet or poured down a drain. To discard the medicine, consult a pharmacist or healthcare provider for instructions on local take-back programs, as disposal must follow local requirements and avoid release to the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Helmizol found in:

A-Z Index: